Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe

Posted on: 16 May 18
  • 400 patients with severe forms of dRTA will be followed as part of the programme
  • Resulting data will be used to better understand issues affecting patient care
  • Advicenne’s lead candidate ADV7103 targets dRTA as first indication


Nîmes, France, 15th May 2018 – Advicenne (Euronext: ADVIC), a specialist pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announces it has entered into a partnership with the European Society for Paediatric Nephrology (ESPN). This partnership, which will initially last for 3 years, will enable data collection on distal Renal Tubular Acidosis (dRTA) in Europe.

This collaboration will be marked by the opening of a survey on the management of dRTA in Europe (mainly covering the 5 largest European countries). The database will gather real-life data on health evolution and care process of 400 dRTA patients with primarily the genetic form of the disease in Europe. The database will be used to provide compelling information on patient journey, diagnostic, alternative treatments and complications arising from dRTA. Data collected will be published to publications with the objective to share its findings with the health community.

Elena Levtchenko, ESPN Secretary General comments: “This partnership reflects our willingness to improve the knowledge available around renal diseases that affect children, and in this case around dRTA. The information gathered will allow us to improve patient journeys and quality of care of patients affected by dRTA in Europe.”

“We are delighted to start this collaboration with ESPN. It reflects our global approach and vision to improve the quality of life of patients with a renal orphan disease.” said Luc-André Granier, co-founder and CEO of Advicenne.

Editor's Details

Mike Wood

Last updated on: 16/05/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.